BioMarker Strategies is a Baltimore-based company that has developed the SnapPath Cancer Diagnostics System, a proprietary and patented technology for predictive tests in the field of personalized medicine. Their innovative system automates and standardizes functional ex vivo profiling of live solid tumor cells, enabling the creation of highly predictive biomarker tests for individual response to targeted treatments for solid tumors.
The company's mission is to make personalized medicine a reality for patients with solid tumor malignancies by collaborating with companies developing targeted therapies. BioMarker Strategies' capabilities are available for preclinical and early clinical studies, allowing for the assessment of pharmacodynamic changes in individual patients' solid tumors.
Generated from the website